Guangzhou Baiyunshan Pharmaceutical Holdings Company (874) Q3 2024 earnings summary

Executive summary

• Operating income for Q3 2024 was RMB 18.02 billion, down 1.08% year-over-year; nine-month revenue reached RMB 59.06 billion, up 1.5% year-over-year.

• Net profit attributable to shareholders for Q3 was RMB 609 million, a 37.82% decrease year-over-year; nine-month net profit was RMB 3.16 billion, down 16.68%.

• Decline in profit attributed to macroeconomic fluctuations, increased market competition, and industry policy impacts affecting subsidiary sales.

Financial highlights

• Basic and diluted EPS for Q3 were RMB 0.375, down 37.82% year-over-year; nine-month EPS was RMB 1.943, down 16.68%.

• Net cash flow from operating activities for the nine months was negative RMB 751 million, a 183.33% decrease year-over-year, mainly due to higher cash outflows for raw materials and drug purchases.

• Total assets as of 30 September 2024 were RMB 79.26 billion, up 0.85% from year-end 2023; total equity attributable to shareholders was RMB 36.22 billion, up 3.73%.

• Operating costs for the nine months increased to RMB 55.41 billion from RMB 53.78 billion year-over-year.

Outlook and guidance

• No explicit forward-looking guidance provided; management notes ongoing macroeconomic and competitive pressures.